Pillstats
Rx only · Kit · Subcutaneous

Adalimumab-Ryvk

Brands: Simlandi

3 ACTIVE SUPPLIERS — US
openFDA · updated weekly
US4 NDCs
3 active makers
UKComing
soon
CAComing
soon
AUComing
soon
EUComing
soon
RxCUI (US)327361
US makers3 labelers
Packages5
DEA / ScheduleNone

US acquisition costNADAC · per unit

Average across 2 priced NDCs. A benchmark of pharmacy acquisition cost — not a retail quote.

$141.72$283.44$425.16$566.88Dec 2025Apr 2026Jul 2026
$492.935
Latest avg · Jul 22, 2026
+1%
Since Dec 17, 2025
3
Active US suppliers
80%
Top-2 supplier share*

Medicaid dispensing volumeSDUD · per quarter

Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume — Medicaid only, not all-payer.

3.2K6.4K9.5K13K2025 Q12025 Q22025 Q32025 Q42026 Q1
11K
Rx · 2026 Q1
26K
Units dispensed
+259%
Rx vs. year ago
5
Quarters · since 2025 Q1

Who makes it3 active · 0 exited

US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.

LabelerTypePackagesStatus
Teva Pharmaceuticals USA, Inc.unknown2SUPPLYING
Quallent Pharmaceuticals Health LLCunknown2SUPPLYING
A-S Medication Solutionsunknown1SUPPLYING

Regulatory & supply events

No recalls, shortages, or registration changes on record for this drug concept.